期刊文献+

多种肿瘤标志物联合检测对肝门胆管癌诊断的意义 被引量:9

Diagnostic value of combination detection of multiple tumor markers for hilar cholangiocarcinoma
原文传递
导出
摘要 目的:探讨联合检测肿瘤标志物CA50,CA125,CA242,CA19-9及CEA对肝门胆管癌诊断的意义。方法:选择近2年间住院且术后病理证实为肝门胆管癌患者90例作为观察组,同期胆道良性病变患者91例作为对照组,采用全自动电化学发光分析仪测定两组患者术前血清中CA50,CA125,CA242,CA19-9及CEA的水平。分别计算两组血清中5种肿瘤标志物的敏感性、特异性及准确性。结果:观察组血清CA50,CA242,CA19-9及CEA的水平明显高于对照组(均P<0.01),而观察组血清CA125水平与对照组血清CA125水平比较无统计学差异(P>0.05)。血清CAl9-9在肝门胆管癌中阳性率最高(86.67%),次为CA242(63.33%)及CA50(60%);两组患者血清中5种标志物的阳性率比较,除CA125外,各相应组间差异具有统计学意义(P<0.05)。对于肝门胆管癌的诊断,血清CA19-9灵敏度最好(93.98%),而CEA的特异度最好(94.60%)。结论:联合检测CA50,CA242,CA19-9和CEA有助于肝门胆管癌与胆道良性疾病鉴别。 Objective: To determine the diagnostic value of the combination detection of the tumor markers, CA50, CA125, CA242, CA19-9 and CEA for hilar cholangiocarcinoma. Methods: Ninety patients admitted to our hospital in the recent two years, who were confirmed having hilar cholangiocarcinoma by postoperative pathology, were included in the observation group, and another group of 91 patients with benign biliary tract diseases hospitalized during the same period served as control group.The serum levels of CA.50, CA125, CA242, CA19-9 and CEA of the two groups were detected by automatic electrochemiluminescence analyzer, and the sensitivities, specificities and accuracies of the five tumor markers of the two groups were determined, respectively. Results: The serum levels of CA50, CA242, CA19-9 and CEA in the observation group were all significantly higher than those of the control group, (all P〈0.01), but the difference of the serum levels of CA125 between the two groups had no statistical significance (P〉0.05). In hilar cholangiocarcinoma, the serum CA19-9showed the highest positive rate (86.67%) among the five markers, followed by CA242 (63.33%), and CA.50 (60%), successively. Between the two groups, the positive rates of the five tumor markers, except for CA125, had significant differences (all P〈0.05). For the diagnosis ofhilar cholangiocarcinoma, serum CA19-9 had thebest sensitivity (93.98%), while CEA had the best specificity (94.60%). Conclusion: Combination detection of CAS0, CA242, CA19-9 and CEA is helpful for differential diagnosis ofhilar cholangiocarcinoma and benign biliary tract diseases.
出处 《中国普通外科杂志》 CAS CSCD 北大核心 2012年第2期140-143,共4页 China Journal of General Surgery
关键词 胆管肿瘤/诊断 肿瘤标志物 诊断 鉴别 Bile Duct Neoplasms/diag Tumor Markers Diagnosis, Differential
  • 相关文献

参考文献9

  • 1Blechacz B,Gores GJ.Cholangiocarcinoma:advances in pathogenesis,diagnosis,and treatment[J].Hepatology,2008,48(1):308-321.
  • 2秦兴雷,李志强,石景森,张练,王作仁,王林.血清和胆汁CA19-9联合检测对诊断胆道良恶性病变的价值[J].中国普外基础与临床杂志,2000,7(3):161-163. 被引量:38
  • 3高明,项和平,耿小平,张长乐.肝门部胆管癌的诊断治疗[J].中国普通外科杂志,2010,19(8):896-898. 被引量:13
  • 4徐岚,周永.大肠癌患者血清CEA、CA199、CA125联合检测的临床意义[C].2006年浙江省医学会检验医学会议论文汇编,2006:304-306.
  • 5Kawa S,Tokko M,Hasebe O,et al.Comparative study of CA242 and CA19-9 for the diagnosis of pancretic cancer[J].Br J Cancer,1994,70:484-486.
  • 6Kuusela P,Haglund C,Roberts PJ,et al.Comparison of a new tumor marker CA242 with CAl9-9,CA50 and carcinoembryonic antigen(CEA)in digestive tract disease[J].Br J Cancer,1991,63:634-640.
  • 7许亚辉.血清肿瘤标志物联合检测对消化系统良恶性疾病的诊断价值[J].中国误诊学杂志,2003,3(4):518-519. 被引量:31
  • 8Patel AH,Harnosis DM,Klee GG,et al.The utility of CA19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis[J].Am J Gastroenterol,2000,95(1):204-207.
  • 9Minton JP,Heohn JL,Gerber DM,et al.Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study[J].Cancer,1985,55(6):1284-1290.

二级参考文献24

  • 1Yang, Wei-Liang,Zhang, Xin-Chen,Zhang, Dong-Wei,Tong, Bai-Feng.Diagnosis and surgical treatment of hepatic hilar cholangiocarcinoma[J].Hepatobiliary & Pancreatic Diseases International,2007,6(6):631-635. 被引量:3
  • 2陈垦,崔淑兰.癌相关糖链抗原的临床意义[J].临床荟萃,1993,8(23):1080-1081. 被引量:5
  • 3夏吉荣,黄天禄,马志如,刘忠.血清CA_(242)测定的临床应用评价[J].中国肿瘤临床,1997,24(1):40-42. 被引量:33
  • 4万文徽,李吉友.肿瘤标志的临床应用[J].中华医学检验杂志,1997,20(1):49-51. 被引量:180
  • 5Hoglund C, RobertsPJ, Kuusela P, et al . Evaluati on of CA19-9 as an serum tumor marker in pancreatic cancer〔J〕. Br J Cancer, 1986; 53(2)∶197
  • 6陆雪龙 王百正 时红珍.CA19—9RIA的临床观察〔J〕[J].放射免疫学杂志,1992,5(4):222-222.
  • 7秦兴雷 石景森 王作仁等.血清和胆汁CA19—9、CEA联合检测在胆道疾病中的对比研究〔J〕[J].中华实验外科杂志,1997,:28-28.
  • 8Ohshio G, Manabe T, Watanable Y, et al. Comparative studies of DU-PAN-2,carcinoembryonic antigen, and CA19-9 in the serum and bile of patie nts with pancreaticand biliary tract disease: evaluation of the influence of ob structive jaundice 〔J〕.Am J Gastroenterol, 1990; 85(10)∶1370
  • 9Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor m arker CA19-9 inacute cholangitis 〔J〕. Dig Dis Sci, 1988; 33(10)∶1223
  • 10Ker CG, Chen JS, Lee KT, et al. Assessment of serum and bile le vels of CA19-9 andCA125 in cholangitis and bile duct carcinoma 〔J〕. J Gastr oenterol Hepatol, 1991; 6(5)∶505

共引文献79

同被引文献77

引证文献9

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部